MBX Biosciences reports FY2025 net loss of $87M; Phase 3 canvuparatide on track for Q3 2026

MBX Biosciences, Inc.

Net loss FY2025 $87.0M vs $61.9M in 2024; R&D expenses $79.2M, up from $57.4M.
Pro forma cash & investments $459.1M including $85.4M ATM net proceeds; runway into 2029.
Phase 3 trial of once-weekly canvuparatide for hypoparathyroidism to initiate Q3 2026 after successful End-of-Phase 2 FDA meeting.
MBX 4291 (obesity) 12-week MAD data expected Q4 2026; two additional obesity candidates to be nominated in Q2 and Q3 2026.
Appointed Laurie Stelzer to Board and Karen Basbaum as CBO in early 2026.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MBX Biosciences, Inc. reported the full year ended December 31, 2025 results: net income $87.0 million.

Period: the full year ended December 31, 2025
Net income: $87.0 million
Result: reported results

Exact text from the filing

Net loss for the full year ended December 31, 2025 was $87.0 million

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

MBX Biosciences, Inc. reported the three months ended December 31, 2025 results: net income $22.1 million.

Period: the three months ended December 31, 2025
Net income: $22.1 million
Result: reported results

Exact text from the filing

Net loss for the three months ended December 31, 2025, was $22.1 million

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

MBX Biosciences, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-103118

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.